| Type | Subsidiary |
| HQ | Buffalo, NY, US |
| Founded | 2015 |
| Website | omniseq.com |
| Cybersecurity rating | BMore |
OmniSeq was founded in 2015 and is headquartered in Buffalo, NY, US
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at OmniSeq
Paul Depietro
Executive Director, Knowledge Informatics
Margot Schoenborn
Chief Executive Officer, Director
Roger D. Klein
Chief Medical Officer
Carl Morrison
Founder
Sean Glenn
SVP, Laboratory Operations and Research Development, Assistant Laboratory Director
Shengle Zhang
Laboratory Director
OmniSeq Office Locations
OmniSeq has an office in Buffalo
Buffalo, NY, US (HQ)
Hauptman Woodward Medical Research Institute, 700 Ellicott St
OmniSeq Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Total Funding | $11.6 m |
Investors | LabCorp |
In total, OmniSeq had raised $11.6 m
OmniSeq Cybersecurity Score
OmniSeq Online and Social Media Presence
646 Twitter followers
OmniSeq has 646 Twitter Followers. The number of followers has increased 2.3% month over month and increased 5% quarter over quarter
OmniSeq's Trends
Twitter Engagement Stats for @OmniSeq
597
Tweets
1.1k
Following
646
Followers
7
Tweets last 30 days
3.9
Avg. likes per Tweet
100%
Tweets with engagement
OmniSeq Company Culture
Overall Culture
C
70/100
CEO Rating
A+
90/100
Compensation
A+
95/100
OmniSeq News and Updates
January 28, 2021
OmniSeq and UPMC Collaborate to Launch Novel Phase II Prospective Head and Neck Cancer Clinical Study
BUFFALO, N.Y., Jan. 28, 2021 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing in oncology, today announced its collaboration with the University of Pittsburgh Medical Center (UPMC) to employ its RNA sequencing (RNA-seq) gene expression profile assay for selecting...
December 01, 2020
OmniSeq Receives ISO Certification for Quality Management Systems
BUFFALO, N.Y., Dec. 1, 2020 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the company has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management Systems (QMS). ISO 13485:2016...
OmniSeq Blogs
January 15, 2021
Medical Laboratory Scientist
POSITION SUMMARY The Medical Laboratory Scientist is responsible for specimen processing, test performance and for reporting test results. Performs high complexity molecular laboratory test procedures in a timely manner as assigned; obtains and interprets data for diagnosis and treatment of disease;…
January 12, 2021
Director, Biopharma Sales & Business Development – Oncology
This position is field based and will promote the company’s genomic and immunoncology portfolio of services targeting early biomarker discovery, translational research, clinical trials, and cancer vaccine development. The Director Biopharma Sales & Business Development will be responsible for se…
December 17, 2020
Research Laboratory Scientist
POSITION SUMMARY Performs supervised simple and complex molecular tests in the Research and Development (R&D) laboratory to optimize oncology-based assay processes; including sample preparation, workflow, automation and analyte detection to support OmniSeq’s molecular diagnostic testing business…
December 03, 2020
Cancer-testis antigen detection by targeted RNA sequencing
Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors. This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as good candidate targets for cance…
December 03, 2020
Cancer testis antigen co-expression landscape in solid tumors
Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for cancer vaccinations and T-cell-ba…
December 03, 2020
PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer
Yong Hee Lee, Grace Dy, Paul DePietro, Jeffrey Conroy, Sarabjot Pabla and Mary Nesline Abstract Background PD-L1 immunohistochemistry (IHC) testing is suboptimal for predicting patient clinical benefit for checkpoint inhibition, while PD-L1 liquid biopsy is not clinically validated and lacks sensiti…
OmniSeq Frequently Asked Questions
When was OmniSeq founded?
OmniSeq was founded in 2015.
Who are OmniSeq key executives?
OmniSeq's key executives are Paul Depietro, Margot Schoenborn and Roger D. Klein.
How many employees does OmniSeq have?
OmniSeq has 45 employees.
Who are OmniSeq competitors?
Competitors of OmniSeq include Bioheng, Sunway and Immunetune.
Where is OmniSeq headquarters?
OmniSeq headquarters is located at Hauptman Woodward Medical Research Institute, 700 Ellicott St, Buffalo.
Where are OmniSeq offices?
OmniSeq has an office in Buffalo.
How many offices does OmniSeq have?
OmniSeq has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies